Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eurasian H5 subtype avian influenza vaccine
- Development stage
- Preclinical
- Lead developer
- Harris Vaccines
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intratracheal, Ophthalmic, In Ovo, Sublingual, Intranasal, Intramuscular, Oral, Inhalation
01
Overview
This vaccine, developed by Harrisvaccines, Inc. and later acquired by Merck Animal Health, is designed to combat the Eurasian H5 subtype of avian influenza. It utilizes proprietary RNA Particle (RP) technology, which allows for rapid development of herd-specific vaccines for emerging diseases. The acquisition by Merck aimed to accelerate its development and broaden its market access.
02
Targets
H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on Eurasian H5 subtype avian influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eurasian H5 subtype avian influenza vaccine.